anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The optimal management of patients presenting with drug-eluting stent (DES) restenosis remains unclear. Data from recent randomized clinical trials have suggested that angioplasty with drug-coated balloons (DCB) is associated with excellent clinical outcomes. However, as the effectiveness of DCB devices depends critically on the specific composition of its matrix coating there may be important differences in clinical performance between different DCB devices. The prospective, non-randomized, single arm, historical-control ISAR-DESIRE 3A trial is designed to test that hypothesis that angioplasty with a novel paclitaxel-coated balloon with citrate-based excipient (Agent PCB, Boston Scientific) will be non-inferior to a conventional paclitaxel-coated balloon with iopromide excipient (SeQuent Please PCB, B. Braun; data from ISAR-DESIRE 3) for the treatment of coronary restenosis after implantation of limus-analogue drug-eluting stents (DES). The key inclusion criteria are patients with symptoms and/or objective signs of ischemia, restenosis at the site of previous limus-analogue DES implantation and written, informed consent. The primary endpoint is in-segment percent diameter stenosis (%DS) at 6-8 month follow-up angiography. Sample size calculation is based on a non-inferiority analysis: %DS of 35% after Both PCB, non-inferiority margin of 7% absolute, 1-sided α-level of 0.05 and power of 80% resulting in 102 patients per group. To account for possible FU losses 125 patients in total will be enrolled.
The body mass index (BMI) is used as the most common and simplest measure to predict obesity. The aim of the study was to compare the BMI method and % BF (body fat) determined by bioimpedance analysis for obesity screening and to evaluate the correlation between these methods. 200 women aged 18-25 years were included in the study. BMI ≥ 25/ ≥ 30 kg/m2 was the criterion for assessment of overweight/obesity. Body fat (BF) in % and kg was determined by bioimpedance analysis. For assessment of obesity by % BF, the criterion was ≥ 30% fat. Based on BMI, 4.5% of women were obese, 14.5% were overweight. According to % BF, up to 30% of women were obese. The largest differences between BMI and % BF categorization were found in the underweight and overweight groups. According to the BMI 43% of women in the underweight category and 34.5% in the overweight category had a % BF in the normal range. By correlation analysis, we found a strong positive statistically significant correlation in women between BMI and BF (%) (rs = 0.782, p < 0.01) and also between BMI and BF (kg) (rs = 0.880, p < 0.01). Both of these methods assess body composition in their own specific way, complement each other, and other combining them, we achieve more accurate results for determining the overall health status of an individual.
BACKGROUND: Cerebral microcirculation disturbance manifested by decrease of cerebral blood flow (CBF) is one of early features of Alzheimer's disease (AD). Shenqi Yizhi prescription (SQYZ) is widely used in the treatment of AD. However, the effect of SQYZ on the early feature of AD is not clarified.
PURPOSE: To explore the effect and mechanism of SQYZ on AD-like behavior from the perspective of early pathological features of AD.
METHODS: The fingerprint of SQYZ was established by ultra-high-performance liquid chromatograph. The improvement effect of SQYZ on Aβ1-42 Oligomer (AβO)-induced AD-like behavior of mice was evaluated by behavioral test. The changes of CBF were detected by laser doppler meter and laser speckle imaging. The pathological changes of the hippocampus were observed by HE staining and transmission electron microscope. The expressions of intercellular communication molecules were detected by western blotting or immunofluorescence staining. The content of platelet-derived growth factor-BB (PDGF-BB) was detected by ELISA. Finally, the core components of SQYZ were docked with platelet-derived growth factor receptor beta (PDGFRβ) using AutoDock Vina software.
RESULTS: The similarity of the components in SQYZ extracted from different batches of medicinal materials was higher than 0.9. SQYZ administration could improve AβO-induced memory impairment and CBF reduction. Compared with the sham group, the number of neurons in the hippocampi of AβO group was significantly reduced, and the microvessels were shrunken and deformed. By contrary, SQYZ administration mitigated those pathological changes. Compared with the sham mice, the expressions of CD31, N-cadherin, PDGFRβ, glial fibrillary acidic protein, phosphorylation of focal adhesion kinase, integrin β1, and integrin α5 in the hippocampi of AβO mice were significantly increased. However, SQYZ administration significantly reduced AβO-induced expression of those proteins. Interestingly, the effect of PDGFRβ inhibitor, sunitinib demonstrated a consistent modulating effect as SQYZ. Finally, the brain-entering components of SQYZ, including ginsenoside Rg5, coptisine, cryptotanshinone, dihydrotanshinone IIA, stigmasterol, and tanshinone IIA had high binding force with PDGFRβ, implicating PDGFRβ as a potential target for SQYZ.
CONCLUSIONS: Our data indicate that SQYZ improves CBF in AβO-triggered AD-like mice through inhibiting brain pericyte contractility, indicating the treatment potential of SQYZ for AD at the early stage.
SC-48334 is a chemical that prevents the biochemical actions of certain enzymes in the body, and recent studies have shown that it may also prevent the activity of HIV. The study will attempt to show whether SC-48334 can safely and effectively break the cycle of HIV infection in AIDS and advanced ARC by progressively eliminating HIV.

Six patients are enrolled sequentially into each of eight different dose levels and the drug is administered by mouth at least 60 minutes before meals according to the following schedule: Day 1: One-quarter of total assigned daily dose. Patients receive the dosage in the hospital as either an inpatient or outpatient and are observed for 12 hours, during which time they are evaluated and blood is drawn for pharmacokinetic studies. Patients return at 24 and 48 hours for a limited physical examination and additional pharmacokinetic studies. Days 4 - 31: Total assigned daily dose, one-quarter 4 times a day. Patients are observed for at least 5 days in the hospital following the start of this part of the program, during which time clinical, laboratory, and pharmacokinetic information is obtained in order to establish baseline values. After the 6th day, patients are evaluated with a complete physical exam, urinalysis, and laboratory studies once a week and a limited physical exam and brief laboratory studies 3 times a week. At each of the eight dose levels, the second and third patients receive their first dose only after the first patient has been followed for 72 hours after receiving the first dose. Patients 4, 5, and 6 begin treatment only after patients 2 and 3 have completed 14 days of the four-part total dose. Patients are treated on an outpatient basis, with 5 to 6 days spent in the hospital for evaluation.
Provided are a core-shell luminescent nanomaterial and a preparation method thereof. The core-shell luminescent nanomaterial has UCNPs as a core and an alkaline manganese compound as a shell. The UCNPs as the core can achieve a fluorescent labeling/imaging function, and the alkaline manganese compound as the shell can enable MRI imaging of a tumor cell. While a small amount of the material might enter a normal cell as a result of the recognition rate being less than 100%, the normal cell will not be detected because the low acidity inside the normal cell prevents the alkaline manganese compound from being dissolved and releasing a manganese ion, and the UCNPs of the core will not be released and so will not affect NMR imaging and fluorescent imaging. This can greatly increase the recognition rate of a tumor cell. The core-shell luminescent nanomaterial can be used in the high-sensitivity fluorescence detection and MRI imaging and analysis of a tumor cell and a tumor tissue, providing more accurate information for medical detection and treatment.
Adalimumab-aacf is a tumor necrosis factor blocker. Adalimumab-aacf is a recombinant human IgG1 monoclonal antibody created using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgG1:k constant regions. Adalimumab-aacf is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary (CHO)) expression system and is purified by a process that includes specific viral inactivation and removal steps. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons. 

Adalimumab-aacf injection is supplied as a sterile, preservative-free solution for subcutaneous administration. The drug product is supplied as either a single-dose, prefilled pen (Adalimumab-aacf Pen), as a single-dose, 1 mL or prefilled glass syringe or as a single dose institutional use vial kit. Enclosed within the pen is a single-dose, 1 mL prefilled glass syringe. The solution of Adalimumab-aacf is clear and colorless to pale yellow, with a pH of about 5.2. 

Each 40 mg/0.8 mL prefilled syringe or prefilled pen, or institutional use vial kit delivers 0.8 mL (40 mg) of drug product. Each 0.8 mL of Adalimumab-aacf contains adalimumab-aacf (40 mg) and glacial acetic acid (0.5 mg), trehalose (54.8 mg), polysorbate 80 (0.8 mg), sodium chloride (2.3 mg), and Water for Injection. Sodium hydroxide is added to adjust pH.
Methods and apparatuses for wireless communication between medical devices are provided. In some embodiments, commodity low power, low bandwidth communication protocols may be utilized to simultaneously convey multiple signals with high fidelity and reliability. For example, cardiac sound data and ECG data may be compressed using a common ADPCM component and inserted into a common BLE packet structure. Command-control data may also be inserted. Where required command-control data reporting frequency is less than the packet frequency, header bits may be utilized to convey multiple types of command-control data in a given packet byte position. Rolling packet sequence values may be inserted into the common packet structure, for use by receiving devices to identify link integrity failures.
The present invention relates to a DNA construct exhibiting β-1,3-glucanase activity, which DNA sequence: a) comprises the DNA sequence shown in SEQ ID no. 1, or b) comprises an analogue of the DNA sequence shown in SEQ ID no. 1, which (i) hybridizes with the same oligonucleotide probe as the DNA sequence shown in SEQ ID No. 1, and (ii) encodes a polypeptide which is homologous with the polypeptide encoded by a DNA sequence comprising the DNA sequence shown in SEQ ID No. 1, or (iii) encodes a polypeptide which is immunologically reactive with an antibody raised against a purified β-1,3-glucanase encoded by the DNA sequence shown in SEQ ID No. 1 derived from Oerskovia Xanthineolytica LLG109. Further the invention relates to an expression vector comprising said DNA construct, a cell harbouring said DNA construct or expression vector, a method of producing the novel enzyme, a novel enzyme and preparation containing said novel enzyme, the use of the enzym for degrading or modification of β-glucan containing material.
BACKGROUND AND AIMS: Acute lower gastrointestinal bleeding (ALGIB) increase with age and the administration of antiplatelet drugs. Colonic diverticular bleeding (CDB) is the most common cause of ALGIB, and endoscopic hemostasis is an effective treatment for massive CDB. But in patients without extravasation on contrast-enhanced computed tomography (CECT), the efficacy of urgent colonoscopy (UCS) is controversial from the point of the clinical course, including rebleeding rate. We aimed to establish a potential strategy including UCS for CDB patients without extravasation on CECT.
PATIENTS AND METHODS: Patients from two centers treated for CDB without extravasation on CECT between July 2014 and July 2019 were retrospectively identified (n = 282). Seventy-four underwent UCS, and 208 received conservative management. We conducted two analyses. The first analysis investigates the risk factors of rebleeding rate within 5 days after administration (very early rebleeding), and no UCS (NUCS) was not the independent factor of the very early rebleeding. The second analysis is whether UCS positively influenced the clinical course after hospitalization.
RESULTS: The prevalence of very early rebleeding and early rebleeding (6-30 days from admission), patients requiring blood transfusion within 0-5 days and 6-30 days post-admission, and duration of hospitalization were examined as clinical course factors between UCS and NUCS group. There was no significant difference between the UCS and non-UCS groups in the clinical course factors. UCS for the CDB patients without extravasation was not improved rebleeding rate and clinical course.
CONCLUSIONS: UCS is not necessary in case ofCDB patient without extravasation on CECT.
FIELD: chemical-pharmaceutical industry, medicine. SUBSTANCE: invention relates to preparation with properties of cardioselective β1-adrenoceptive antagonist. The proposed composite comprises atenolol, magnesium carbonate, aerosil, microcrystalline cellulose, starch, calcium stearate, talc, sodium lauryl sulfate and hydroxypropylcellulose. Invention provides preparing pharmaceutical composition satisfying to Pharmacopoeia requirements. EFFECT: valuable medicinal properties, stability at storage. 2 ex
This is a multi-center, open-label, phase II study to evaluate the anti-tumor activity and safety of bicalutamide administered orally daily to patients with estrogen receptor (ER)-negative/ progesterone receptor (PgR)-negative/ androgen receptor (AR)-positive metastatic breast cancer. Eligible patients will receive bicalutamide at a dose of 150mg PO daily.
PURPOSE:To obtain a new peptide, a neuropeptide similar to tachykinin, not only useful as a biochemical reagent but also providing a new approach to medicines and agricultural chemicals. CONSTITUTION:A new peptide of amino acid sequence formula (1) or (2). H-Leu- Arg-Gln-Ser-Gln-Phe-Val-Gly-Ser-Arg-NH2. (1). H-Ala-Ala-Gly-Met-Gly-Phe-Phe- Gly-Ala-Arg-NH2 (2). (In the formula, amino acid residues are shown by three letters decided by IUPAC and IUB and NH2 indicates that C end is amidated). This peptide is a neuropeptide similar to tachykinin showing contraction activity against inner ring-like muscle of body wall of Urechis unicinctus and contraction activity against hindgut of Perpilanta americana Linn., is obtained from nerve cord of Urechis unicinctus and is also synthesized by an automatic peptide synthesizing machine on the market.
An aspect of some embodiments of the current invention relates to a patch having a mechanism to refresh a fragrance and/or odor control. For example, the patch may have a have multiple reservoirs of fragrance and/or solvent. Optionally, when one reservoir has expired another can be activated. Optionally, the patch is effective without the fragrant chemicals and/or solvent contacting the user. In some embodiments, a skin patch includes a volatilization area and/or a reservoir containing fragrance and/or volatile solvent. Optionally, the patch is activated after it is placed on the skin. For example, the patch may be activated by moving the solvent and/or the fragrance to the volatilization area.
Typhoid fever is a generalized infection of the reticuloendothelial system (spleen, liver, and bone marrow), gut-associated lymphoid tissue and gall bladder caused by Salmonella enterica serovar Typhi (S typhi). Humans are the only known natural host and reservoir for S typhi. Typhoid bacilli are transmitted by the fecal-oral route by contaminated drinking water or food. The ideal typhoid vaccine would combine high levels of durable protective immunity with simplicity of administration and minimal reactogenicity. The primary objective of this study is to assess the safety of Ty800 oral typhoid vaccine when administered as a single dose over a range of doses (5 x 10\^7, 5 x 10\^8, and 5 x 10\^9 cfu) in healthy adult subjects compared to placebo. The primary endpoint is safety of Ty800 at the dose levels administered compared to placebo as determined by absence of bacteremia, absence of the diagnosis of typhoid fever as confirmed by a positive blood culture for the Ty800 vaccine organism, and by verifying that the null phoP/phoQ phenotype is retained by the isolated shed vaccine organism. Safety variables will be assessed by the reported incidence of adverse events (AE), blood cultures, and changes in vital signs, physical examination, and routine laboratory parameters over time at each vaccine dose level compared to placebo. The secondary objectives of this study are: to evaluate the immunogenicity of a single oral dose administration of Ty800 over a range of doses in healthy adult subjects; to evaluate the Ty800 vaccine dose response by comparing the immunogenicity profiles of each dose level; and to evaluate the shedding profile of Ty800 by determining the quantity and duration of shedding for each dose level. The tertiary objectives of this study include: evaluating, in a substudy, single nucleotide polymorphisms (SNPs) in candidate genes, e.g., IL-8 and interferon gamma, that may influence the immune response or persistent shedding of the vaccine organism and evaluating the induction of memory B cells in the vaccinated subjects. This study is a randomized, double-blind, placebo-controlled, dose escalation, inpatient phase I/II clinical trial. Three dose levels of Ty800 a vaccine will be evaluated and compared to placebo. Prior to randomization and administration of study vaccine, subjects will undergo screening evaluations. Healthy subjects meeting study eligibility criteria will be admitted to an inpatient facility with appropriate isolation containment the day prior to randomization, and they will remain in the unit for approximately 10 consecutive days. Three cohorts of 18 volunteers, representing 3 escalating doses of Ty800 typhoid vaccine will be challenged. In each cohort, 12 volunteers will receive Ty800 as a single oral dose, and 6 volunteers will receive placebo. Dose escalation will occur in a stepwise fashion and will be dependent upon the assessment of safety parameters and by meeting criteria for advancement to the next dose. Participants will be involved in study related procedures for up to 7 months.
FIELD: medicine, endocrinology. SUBSTANCE: invention relates to insulin preparation that includes human insulin crystals, ultraband and zinc at total concentration in the preparation from 0,5 to 20 mg per 100 U of insulin. Preparation shows pH value 6.0-7.4 and does not contain any other proteins similar to insulin. Preparation modified with zinc shows properties of human insulin that can be stored for a long time. EFFECT: improved properties of insulin preparation. 9 cl, 8 tbl, 7 ex
When microglia become activated they express peripheral benzodiazepine receptors (PBR) or binding sites on their mitochondrial membrane. PBRs are functionally and structurally distinct from central benzodiazepine receptors associated with y-aminiobutric acid (GABA)-regulated chloride channels. PBRs are found in abundance in peripheral organs and hematologic cells, but are present at only very low levels in the normal central nervous system (Banati, 2002). CLINDE is a phenylimidazopyridine and appears to bind selectively to the PBR. In the absence of excessive blood in the CNS an increase CLINDE binding to PBR is a potential marker of microglial activation in the CNS. The increase in CLINDE binding may be an indicator of the transition of microglia from a resting to an activated state. When labeled with 123-I and used as a SPECT radiotracer, CLINDE may serve as an in vivo marker of microglial activation in Alzheimer disease and Parkinson disease.

The 123-I radioactive tag offers distinct advantages for large-scale clinical imaging studies of anti-inflammatory targeted treatments as a marker of microglial activation and efficacy of therapeutic intervention. The half-life (13.1 h) of 123-I permits imaging in multiple subjects in a single research-dedicated imaging center, with multiple research subjects per day. This minimizes variability introduced in multi-center quantitative imaging trials where different cameras, image processing methods, and QA procedures all conspire to increase the variance imaging biomarkers. Using this model, our group pioneered a method to evaluate the loss of dopamine function in Parkinson's disease using a radioactive drug 123-I β-CIT which binds directly to dopamine nerve terminals.

The adaptation of imaging agents like 123-I CLINDE as a biomarker of microglial activation in neurodegenerative diseases requires human validation studies. Expanding upon our previous work with b-amyloid ligands (123I-IMPY, 123-I MNI-187) for AD and dopamine transporter ligands (123-I B-CIT, Altropane) for PD, we desire to develop and characterize 123-I CLINDE as a potential marker for microglial activation in association with neuronal damage that may be applicable to multiple neurodegenerative diseases. Ultimately a marker of microglial activation could be used for large-scale quantitative brain imaging trials in AD or PD, specifically to investigate the agent as an objective biomarker in treatments aimed at reducing inflammatory changes in these conditions. The significance of this work lies in applying state-of-art quantitative neuroimaging tools to develop a relevant biomarker in individuals with neurodegenerative diseases with the intention of using this efficiently in large clinical imaging trials.
The original English version of the Western Ontario Shoulder Instability Index will be translated and culturally adapted .Among Shoulder Instability population, Western Ontario Shoulder Instability Index will provided to 90 participants which will be choose through convenience sampling technique . This sampling method based on pre-defined inclusion and exclusion criteria .To check intra-observer reliability of the final Urdu Translation of Western Ontario Shoulder Instability Index, Disability of Arm, Shoulder, and Hand Questionnaire, Walch-Duplay score, Rowe score and Visual Analogue Scale questionnaires will be filled at the same day by two observers for test inter-observers assessment second application will be applied after 35 minutes of first application. Third assessment will be performed after seven days by first observer. Data will be entered and analyzed by using Statistical Package of Social Sciences Version 24 . Internal consistency will be analyzed with Cronbach's alpha value . Intra-class correlation coefficient will be used to check retest reliability. Urdu Translation of Western Ontario Shoulder Instability Index will be evaluated for content validity ,construct validity ,criterion validity and responsiveness.
The invention discloses a kind of medical safety retroactive methods and system based on block chain, and S1. is by medical data storage on the host node of block chain；When S2. seeing a doctor, medical institutions acquire medical data；S3. expert and doctor formulate medical scheme according to medical data and sign, and record storage to block chain and is broadcasted；S4. judge the state of an illness；If the state of an illness is lighter, drug is got, treatment is completed in the infusion of Zai Qu nurse station；Otherwise operative treatment is arranged, preoperative physical condition inspection is carried out, result is stored into block chain, S5 is entered step；S5. implement operative treatment, perioperative signature data are stored into block chain；S6. after treating, time recording clothes for patients drug condition and vital sign are stored on block chain and real-time update；S7. after patient discharge, the daily medicining condition of patient is recorded in real time, is saved to block chain.It is an advantage of the current invention that information anonymity and decentralization using block chain technology form information sharing so that medical institutions obtain medical data under the premise of allowing by patient, through private key.